Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies
HACKENSACK, NJ – September 18, 2017 – Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the publication entitled “Patient-derived xenografts (PDX) effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors” in the journal Annals of Oncology. Annals of Oncology is published by the European Society for Medical oncology (ESMO), the leading European professional organization for medical oncology in Europe. Building on earlier clinical correlation data, this study further demonstrates that PDX models accurately predict patient response to oncology drugs with remarkable 85% positive predictive value.
In the published study, tumors obtained from surgical or biopsy procedures from 237 cancer patients with a variety of solid tumors (including breast, colorectal, ovarian, lung, gastroesophageal, pancreatic cancer and sarcoma) were implanted into immunodeficient mice to establish individual PDX models. Treatment responses in the corresponding PDX models were compared with 129 treatments that were administered to the same patients clinically. In addition, consistent with the existing literature, PDX models faithfully preserved the genetic landscape of the original parental tumor.
“Patient responses correlated well with matching PDXs in a large, heterogeneous population thus demonstrating the utility of this platform for preclinical drug-testing and personalized cancer treatment. Our experience shows us that these models are an accurate tool that can be used in planning clinical trials, identifying patient populations most likely to benefit from oncology therapeutics, and biomarker development”, said Angela Davies, M.D., Chief Medical Officer at Champions Oncology. “We would like to thank our collaborators and patients that contributed to this dataset, creating a valuable PDX resource for the oncology community.”
Manuel Hidalgo, M.D., Ph.D., Professor of Medicine at Harvard Medical School, noted that “Pharma should be adopting greater use of larger PDX cohorts to “simulate” clinical trials early in drug development. As demonstrated in this study, the molecular correlation of these models with the primary tumor is extremely high allowing us to identify key markers for trial success and personalized treatments.”
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune-deficient mice to create TumorGrafts that preserve the biological characteristics of the original human tumor to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. For more information, please visit www.championsoncology.com.
Brett Maas, Hayden IR (646) 536-7331 [email protected]
James Carbonara, Hayden IR (646)-755-7412 [email protected]